TPT topotecan
Features: chemotherapy drug that inhibits DNA topoisomerase I
Description: <p><b>Topotecan</b> — Semisynthetic camptothecin analogue and conventional cytotoxic chemotherapy drug that inhibits DNA topoisomerase I (TOP1). Topotecan stabilizes the transient TOP1-DNA cleavage complex and prevents religation of single-strand DNA breaks. During DNA replication, these trapped complexes can generate lethal double-strand DNA damage and trigger cell death.</p>
<p><b>Drug class:</b> Conventional chemotherapy / topoisomerase I inhibitor / camptothecin analogue.</p>
<p><b>Primary cancer uses:</b> Used clinically in selected ovarian cancer, small-cell lung cancer, and cervical cancer settings. It is also investigated in additional solid and hematologic malignancies.</p>
<p><b>Typical mechanisms:</b> TOP1 inhibition ↑; TOP1-DNA cleavage complexes ↑; DNA single-strand breaks ↑; replication-associated double-strand DNA breaks ↑; replication stress ↑; S-phase cytotoxicity ↑; apoptosis ↑; proliferation ↓.</p>
<p><b>Typical cancer direction:</b> Anticancer activity is associated with TOP1 trapping and DNA damage ↑, leading to tumor-cell proliferation ↓ and cell death ↑.</p>
<p><b>Important toxicities:</b> Myelosuppression is a major dose-limiting toxicity, particularly neutropenia, anemia, and thrombocytopenia.</p>
<p><b>Recommended abbreviation:</b> Topotecan; TPT is used in some literature but should be used cautiously because it is not unique.</p>
<p><b>Brand name:</b> Hycamtin.</p>